Shopping Cart 0
Cart Subtotal
USD 0

Wellcome Trust - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Summary

Wellcome Trust (Wellcome) is a charity that funds research organizations and research communities. It offers funding schemes to support individual researchers, teams and resources. The trust provides funds in areas of biomedical science, public engagement, humanities, innovations, social science, population health, and product development and applied research. It services include funding, grant management, education resources, and investment. The trust offers its education services for PhD students, post-docs and clinicians. It supports scientists, educators, innovators, and artists across the world. The trust works with partner organizations such as academia, business, governments, philanthropy, and civil society. Wellcome is headquartered in London, the UK.

Wellcome Trust-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Wellcome Trust, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Wellcome Trust, Medical Devices Deals, 2012 to YTD 2018 10

Wellcome Trust, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Wellcome Trust, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

Karuna Pharma Raises USD42 Million in Series A Financing 14

Corinnova Raises USD6.1 Million from Wellcome Trust 16

Azellon Raises USD2 Million in Venture Financing 17

Kymab Raises USD100.5 Million in Series C Financing 19

Aurum Biosciences Raises USD4.5 Million in Venture Financing 21

Nabriva Therapeutics Raises USD120 Million in Series B Financing 22

Kymab Raises USD40 Million in Series B Financing 24

Pcovery Raises USD4 Million in Venture Financing 25

Biocartis Raises USD 40.5 Million In Series E Financing 26

Pcovery Raises USD5.7 Million in Seed Financing 28

Trino Therapeutics Raises USD 12 Million In Series A Financing 29

Canbex Therapeutics Raises USD 3 Million In Venture Financing 31

Partnerships 32

Sigma-Aldrich Enters into Agreement with Sanger Institute 32

AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 33

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 34

Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 35

Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 37

Licensing Agreements 38

Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 38

Oxford Gene Enters into Licensing Agreement with Wellcome Trust Sanger Institute 39

Equity Offering 40

Microbiotica Spin Off from Wellcome Trust Sanger Institute 40

Debt Offering 41

Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41

Asset Transactions 42

Orion Biotechnology Switzerland Acquires 5P12-RANTES Molecule from Mintaka and Wellcome Trust 42

Acquisition 43

Ergomed Acquires Haemostatix 43

GlaxoSmithKline Acquires Remaining Stake in GlycoVaxyn for USD190 Million 45

Wellcome Trust-Key Competitors 47

Wellcome Trust-Key Employees 48

Wellcome Trust-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Recent Developments 50

Government and Public Interest 50

Aug 07, 2018: LSHTM to lead vital research into severe corneal infections in low and middle-income countries 50

May 24, 2018: Bristol Professor awarded GBP1.5 million to look deeper into our cell's quality control mechanism 51

May 01, 2018: USD 4.6M boost in search for new malaria drugs 52

Dec 11, 2017: Scientists discover new way to help nerve regeneration in spinal cord injury 54

Dec 08, 2017: GBP3.9m project to support elimination of the world's leading infectious cause of blindness 55

Nov 15, 2017: Improving clinical trials with machine learning 57

Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 58

Sep 15, 2017: 'Exciting' discovery on path to develop new type of vaccine to treat global viruses 61

Aug 30, 2017: Tracing single brain cancer cells simplifies complexity of incurable brain cancers, suggesting new treatments, international study finds 63

Aug 07, 2017: CARB-X Funds Scientists Discovering New Antibiotics to Treat Deadly Superbugs 65

Jan 16, 2017: Cancer genetics refine treatment decisions 67

Other Significant Developments 69

Mar 28, 2018: As the GHIT Fund Closes Out First Five Years of R&D for Lifesaving Medical Breakthroughs, It Launches Next Phase, Focusing on Access and Delivery, Bringing Total Investment to 13.2 Billion Yen (USD 123 Million) 69

Dec 07, 2017: New mental health research framework announced 72

Appendix 73

Methodology 73

About GlobalData 73

Contact Us 73

Disclaimer 73


List Of Figure

List of Figures

Wellcome Trust, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Wellcome Trust, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Wellcome Trust, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Wellcome Trust, Pharmaceuticals & Healthcare, Key Facts 2

Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Wellcome Trust, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Wellcome Trust, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Wellcome Trust, Deals By Therapy Area, 2012 to YTD 2018 9

Wellcome Trust, Medical Devices Deals, 2012 to YTD 2018 10

Wellcome Trust, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Karuna Pharma Raises USD42 Million in Series A Financing 14

Corinnova Raises USD6.1 Million from Wellcome Trust 16

Azellon Raises USD2 Million in Venture Financing 17

Kymab Raises USD100.5 Million in Series C Financing 19

Aurum Biosciences Raises USD4.5 Million in Venture Financing 21

Nabriva Therapeutics Raises USD120 Million in Series B Financing 22

Kymab Raises USD40 Million in Series B Financing 24

Pcovery Raises USD4 Million in Venture Financing 25

Biocartis Raises USD 40.5 Million In Series E Financing 26

Pcovery Raises USD5.7 Million in Seed Financing 28

Trino Therapeutics Raises USD 12 Million In Series A Financing 29

Canbex Therapeutics Raises USD 3 Million In Venture Financing 31

Sigma-Aldrich Enters into Agreement with Sanger Institute 32

AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 33

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 34

Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 35

Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 37

Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 38

Oxford Gene Enters into Licensing Agreement with Wellcome Trust Sanger Institute 39

Microbiotica Spin Off from Wellcome Trust Sanger Institute 40

Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41

Orion Biotechnology Switzerland Acquires 5P12-RANTES Molecule from Mintaka and Wellcome Trust 42

Ergomed Acquires Haemostatix 43

GlaxoSmithKline Acquires Remaining Stake in GlycoVaxyn for USD190 Million 45

Wellcome Trust, Key Competitors 47

Wellcome Trust, Key Employees 48

Wellcome Trust, Subsidiaries 49

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com